Historic Price Achievement and Market Performance
On 13 Mar 2026, Torrent Pharmaceuticals Ltd. closed at Rs. 4,461.55, just 0.19% shy of its 52-week high of Rs. 4,470.00, marking the highest price level ever recorded for the stock. This achievement underscores the company’s consistent upward trajectory, supported by a bullish technical trend that has been in place since 23 Dec 2025 when the stock was trading at Rs. 3,812.
The stock has outperformed the broader market significantly, with a 1-day gain of 0.38% compared to the Sensex’s decline of 0.72%. Over the past week, Torrent Pharma surged 3.56% while the Sensex fell 4.35%. The momentum continued over longer periods, with the stock delivering 9.51% returns in one month versus the Sensex’s negative 8.64%, and an impressive 17.74% over three months against the Sensex’s 11.47% decline.
Year-to-date, Torrent Pharmaceuticals has gained 16.13%, contrasting with the Sensex’s 11.42% loss. The stock’s performance over the last year has been particularly notable, generating 45.69% returns compared to the Sensex’s modest 2.24%. Over three and five years, the stock has delivered extraordinary returns of 195.97% and 262.21% respectively, far outpacing the Sensex’s 29.61% and 48.62% gains. Over a decade, the stock’s appreciation stands at a remarkable 592.55%, dwarfing the Sensex’s 205.38% rise.
Technical and Trading Insights
The stock’s technical indicators present a bullish outlook, with Torrent Pharmaceuticals trading above all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Key technical signals such as MACD, Bollinger Bands, and Dow Theory remain bullish on both weekly and monthly timeframes. The stock’s immediate support level is Rs. 3,038.55, the 52-week low, while resistance levels include Rs. 4,313.87 (20 DMA) and the 52-week high of Rs. 4,470.00.
Delivery volumes have shown a positive trend, with a 1-month delivery volume increase of 31.49% and a 1-day delivery change of 20.16% compared to the 5-day average, indicating sustained investor participation in the stock.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
Financial Strength and Quality Metrics
Torrent Pharmaceuticals is classified as a large-cap company within the Pharmaceuticals & Biotechnology sector, boasting a Market Mojo Score of 77.0 and a current Mojo Grade of Buy, upgraded from Hold on 23 Dec 2025. The company’s financial quality is rated as good, reflecting strong management efficiency and a robust balance sheet.
The company’s return on capital employed (ROCE) stands at a high 24.08%, with a half-yearly peak of 27.85%, indicating effective utilisation of capital. The operating profit to interest coverage ratio is exceptionally strong at 24.18 times, underscoring the firm’s ability to comfortably service its debt. The debt to EBITDA ratio remains low at 1.01 times, and the debt-equity ratio is at a conservative 0.33 times, highlighting prudent leverage management.
Net sales for the latest quarter reached a record Rs. 3,303 crores, with operating profit before depreciation and interest (Pbdit) at Rs. 1,088 crores and profit before tax (excluding other income) at Rs. 837 crores. The company’s net profit for the quarter was Rs. 642.80 crores, marking the highest quarterly earnings to date. Earnings per share (EPS) for the quarter stood at Rs. 18.76.
Dividend metrics reveal a payout of 56.67% with a dividend yield of 0.65%, and the latest dividend declared was Rs. 29 per share, with an ex-dividend date of 18 Feb 2026. Institutional holdings are substantial at 25.28%, reflecting confidence from well-resourced investors.
Valuation and Growth Considerations
The stock trades at a price-to-earnings (P/E) ratio of 65 times (TTM), with a price-to-book value (P/BV) of 17.78 times. Enterprise value multiples include EV/EBITDA at 36.54 times and EV/Capital Employed at 14.53 times. The PEG ratio stands at 2.72, indicating a valuation premium relative to earnings growth.
Over the past five years, the company’s net sales have grown at a compound annual growth rate (CAGR) of 9.72%, while EBIT growth averaged 13.39%. The company’s sales to capital employed ratio is 0.92x, and the tax ratio is 24.47%. The dividend payout ratio remains consistent, supporting shareholder returns.
Despite the premium valuation, Torrent Pharmaceuticals trades at a discount compared to its peers’ historical averages, reflecting market recognition of its quality and growth profile. The company has delivered positive results for ten consecutive quarters, with net profit growth of 7.45% in the most recent period ending December 2025.
Want to dive deeper on Torrent Pharmaceuticals Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Long-Term Performance and Market Standing
Over the last decade, Torrent Pharmaceuticals has demonstrated exceptional growth and value creation, with returns of 592.55% compared to the Sensex’s 205.38%. The company ranks among the top 1% of all 4,000 stocks rated by MarketsMojo, positioned 6th among large-cap stocks and 40th across the entire market. This ranking reflects its consistent financial performance, strong management, and market leadership within the Pharmaceuticals & Biotechnology sector.
The company’s consistent dividend payments, strong return on equity averaging 22.06%, and absence of promoter share pledging further reinforce its quality credentials. Institutional investors hold a significant stake, which often correlates with rigorous fundamental analysis and confidence in the company’s prospects.
While the company’s sales growth rate over five years is moderate at 9.72%, its profitability metrics and capital efficiency remain robust. The stock’s valuation metrics suggest a premium, yet it continues to trade at a discount relative to peer historical averages, reflecting a balanced market assessment of its strengths and growth trajectory.
Summary of Key Financial and Quality Indicators
Torrent Pharmaceuticals exhibits a strong financial profile characterised by:
- High ROCE of 24.08% and half-yearly peak of 27.85%
- Low debt levels with a debt to EBITDA ratio of 1.01 times and debt-equity ratio of 0.33 times
- Consistent profitability with ten consecutive quarters of positive results
- Strong operating profit to interest coverage ratio of 24.18 times
- Robust institutional ownership at 25.28%
- Dividend payout ratio of 56.67% with steady dividend yield
These factors collectively underpin the stock’s all-time high price, reflecting a company that has delivered sustained value to shareholders through operational excellence and financial discipline.
Conclusion
Torrent Pharmaceuticals Ltd.’s ascent to its all-time high stock price is a testament to its enduring strength in the Pharmaceuticals & Biotechnology sector. The company’s solid financial metrics, consistent earnings growth, and strong market positioning have driven this milestone. While valuation multiples indicate a premium, the stock’s performance relative to the broader market and its peers highlights its quality and resilience. This achievement marks a significant chapter in the company’s market journey, reflecting both its historical success and current standing as a leading large-cap pharmaceutical entity.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
